Semaglutide vs Tirzepatide: Comparing GLP-1 Therapies

The GLP-1 Revolution

The glucagon-like peptide-1 (GLP-1) receptor agonist class has fundamentally reshaped the treatment of type 2 diabetes and obesity. Two molecules dominate the landscape: semaglutide (Novo Nordisk's Ozempic/Wegovy) and tirzepatide (Eli Lilly's Mounjaro/Zepbound). While both target the GLP-1 receptor, their pharmacological profiles differ meaningfully, and understanding these differences is essential for optimal patient care.

Mechanism of Action: Single vs Dual Agonism

Semaglutide is a selective GLP-1 receptor agonist. It mimics the action of endogenous GLP-1, binding to GLP-1 receptors in the pancreas (stimulating glucose-dependent insulin secretion), the brain (promoting satiety via hypothalamic and brainstem circuits), and the GI tract (slowing gastric emptying). Its long half-life of approximately 7 days is achieved through albumin binding facilitated by a C-18 fatty acid side chain (Lau et al., 2015, Journal of Medicinal Chemistry; PMID: 26308095).

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first approved molecule in this class. In addition to GLP-1 receptor activation, tirzepatide potently activates glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP signaling adds complementary metabolic benefits: enhanced insulin secretion, improved fat metabolism, and potentially direct effects on adipose tissue that promote fat utilization. The GIP component may also mitigate some of the nausea associated with pure GLP-1 agonism (Samms et al., 2021, Diabetes; PMID: 34376573).

Clinical Trial Data: Weight Loss

The STEP and SURMOUNT trial programs provide the most robust comparative data, though direct head-to-head trials between the two molecules have been limited.

Semaglutide 2.4 mg (Wegovy): In the STEP 1 trial, semaglutide produced a mean weight loss of 14.9% versus 2.4% with placebo over 68 weeks in adults with obesity (Wilding et al., 2021, NEJM; PMID: 33567185). The STEP 5 trial demonstrated durability, with participants maintaining a 15.2% weight reduction at 104 weeks.

Tirzepatide (Zepbound): In the SURMOUNT-1 trial, tirzepatide at the highest dose (15 mg) produced a mean weight loss of 22.5% versus 2.4% with placebo over 72 weeks (Jastreboff et al., 2022, NEJM; PMID: 35658024). The 10 mg dose achieved 19.5%, and even the lowest 5 mg dose produced 15.0% — comparable to semaglutide's maximum dose.

While cross-trial comparisons have inherent limitations (different patient populations, endpoints, and timeframes), the data consistently suggests tirzepatide produces greater absolute weight loss, likely attributable to the additive effects of dual GIP/GLP-1 agonism.

Glycemic Control

Both molecules demonstrate excellent glycemic efficacy. In the SURPASS trial program, tirzepatide reduced HbA1c by 2.0-2.6% depending on dose, with up to 97% of patients achieving HbA1c below 7.0%. Semaglutide in the SUSTAIN trials reduced HbA1c by 1.5-1.8%. The SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1 mg, showed tirzepatide superiority at all doses for both HbA1c reduction and weight loss (Frias et al., 2021, NEJM; PMID: 34170647).

Cardiovascular Outcomes

Semaglutide has established cardiovascular benefit. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in overweight/obese adults without diabetes (Lincoff et al., 2023, NEJM; PMID: 37952131). This was a landmark finding that expanded the clinical rationale beyond glycemic control and weight loss.

Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results expected in late 2026. Early signals from metabolic parameters — improvements in triglycerides, inflammatory markers, and blood pressure — are encouraging, but definitive MACE data is pending.

Side Effect Profiles

Both molecules share a similar gastrointestinal side effect profile, which is class-related:

• Nausea: Semaglutide ~44%, Tirzepatide ~25-33% (dose-dependent)
• Vomiting: Semaglutide ~24%, Tirzepatide ~10-15%
• Diarrhea: Similar rates (~30%) for both
• Constipation: Slightly higher with tirzepatide

Tirzepatide appears to have modestly lower rates of nausea and vomiting, which some researchers attribute to the GIP component's modulatory effects on the emetic pathway. Both require gradual dose titration to minimize GI side effects — a process that typically takes 16-20 weeks to reach the maintenance dose.

Rare but serious risks shared by both include pancreatitis (incidence < 0.5%), gallbladder disease, and a theoretical concern about medullary thyroid carcinoma based on rodent studies (boxed warning for both). Neither should be used in patients with a personal or family history of MTC or MEN2 syndrome.

Practical Considerations for Providers

Dosing frequency: Both are once-weekly subcutaneous injections, making them equivalent in terms of patient convenience.

Dose titration: Semaglutide follows a 4-week escalation (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg for the weight management indication). Tirzepatide follows a similar pattern (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Some clinicians find tirzepatide's additional intermediate doses allow for more granular titration.

Supply and access: Both molecules have faced significant supply constraints due to unprecedented demand. As of early 2026, supply has largely stabilized, though regional shortages persist. Insurance coverage varies widely; prior authorization requirements are common for weight management indications.

Compounded versions: Following the FDA's 2024 decisions regarding compounding of semaglutide and tirzepatide, providers should stay current on the regulatory status of compounded versions. The Peptide Association's regulatory updates track this evolving landscape.

Which One to Choose?

The choice between semaglutide and tirzepatide depends on clinical context:

• Choose semaglutide when: Cardiovascular risk reduction is a primary goal (established MACE benefit); the patient has a history of GI sensitivity (lower overall discontinuation rates in real-world data); insurance coverage favors it.
• Choose tirzepatide when: Maximum weight loss is the primary goal; the patient has significant insulin resistance (dual mechanism may offer advantages); GI tolerability during titration is a concern.

Ultimately, both are transformative therapies. The decision should be individualized based on the patient's metabolic profile, comorbidities, insurance coverage, and treatment goals, made collaboratively between provider and patient.